NCT06140927 Effect of Ketamine on Intraoperative Motor Evoked Potentials
| NCT ID | NCT06140927 |
| Status | Recruiting |
| Phase | Phase 3 |
| Sponsor | University of California, San Francisco |
| Condition | Spine Fusion |
| Study Type | INTERVENTIONAL |
| Enrollment | 20 participants |
| Start Date | 2023-12-01 |
| Primary Completion | 2026-12-01 |
Eligibility & Interventions
Eligibility Fast-Check
Enter your details for a quick preliminary check. This does not replace medical advice.
What to Expect as a Participant
You will actively receive the study intervention — which may be a drug, biologic, device, or procedure.
Phase 3 trials are large pivotal studies comparing the treatment to current standard of care or placebo. Your participation directly contributes to the evidence needed for regulatory approval.
This trial targets 20 participants in total. It began in 2023-12-01 with a primary completion date of 2026-12-01.
⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.
Brief Summary
The goal of this clinical trial is to learn about the effect of ketamine on intraoperative motor evoked potentials in adult patients undergoing thoracolumbar spinal fusions. Participants will undergo a standard anesthetic. In addition to the standard anesthetic, the patients will be administered increasing doses of ketamine with motor-evoked potentials being measured at each dose, to assess any impacts.
Eligibility Criteria
Inclusion Criteria: * Adult patients (\>18 years of age) undergoing posterior spinal fusions. Exclusion Criteria: * Sensitivity or allergy to ketamine. * Schizophrenia or other psychotic conditions * Uncontrolled hypertension with systolic blood pressure greater than 180 mmHg * Myocardial Infarction * Large vascular aneurysms * Patients on ketamine as outpatient therapy.
Contact & Investigator
Marc Buren, MD
PRINCIPAL INVESTIGATOR
University of California, San Francisco
Frequently Asked Questions
Who can join the NCT06140927 clinical trial?
This trial is open to participants of all sexes, aged 18 Years or older, up to 100 Years, studying Spine Fusion. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.
What phase is the NCT06140927 trial and what does that mean for participants?
Phase 3 trials are large-scale studies comparing the new treatment to existing standards of care or a placebo. They provide the evidence needed for regulatory approval. This trial targets 20 participants.
Is NCT06140927 currently recruiting?
Yes, NCT06140927 is actively recruiting participants. Contact the research team at marc.buren@ucsf.edu for enrollment information.
Where is the NCT06140927 trial being conducted?
This trial is being conducted at San Francisco, United States.
Who is sponsoring the NCT06140927 clinical trial?
NCT06140927 is sponsored by University of California, San Francisco. The principal investigator is Marc Buren, MD at University of California, San Francisco. The trial plans to enroll 20 participants.